Literature DB >> 23042845

A 24-year-old Ethiopian farmer with burning feet.

Benjamin Jelle Visser, Daniel Arnoldus Korevaar, Janneke van der Zee.   

Abstract

Podoconiosis is a non-infectious tropical disease caused by exposure of bare feet to irritant alkalic clay soils. This causes an asymmetrical swelling of the feet and lower limbs due to lymphoedema. This swelling is called "elephantiasis" and may lead to severe disability of the patient. It is found in areas of tropical Africa, Central and South America and north-west India, where such soils coexist with high altitude, high seasonal rainfall and low income. Social stigmatization of people with the disease is widespread and economic losses are enormous. Podoconiosis is unique in being an entirely preventable non-communicable tropical disease. However, so far it has received little attention from health care policy makers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23042845      PMCID: PMC3516304          DOI: 10.4269/ajtmh.2012.12-0405

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


A 24-year-old farmer presented to a clinic in north-west Ethiopia (Amhara region) with an 8-year history of progressive edema, moss-like papillomas, hard nodules, and hyperkeratosis involving his feet (Figure 1), which were now increasingly itching and burning. An in vitro immunodiagnostic assay for the detection of Wucheria bancrofti was negative. The clinical presentation of elephantiasis, in the absence of filarial worms, prompted the diagnosis of podoconiosis, also known as “mossy foot disease” or “endemic non-filarial elephantiasis.” Podoconiosis affects 4 million people worldwide and is endemic in areas of tropical Africa, Central and South America, and India. It is associated with living in areas with high altitude and high seasonal rainfall, and is caused by exposure of bare feet to alkaline volcanic clay soils.1 Mineral particles are thought to penetrate the skin, causing an inflammatory reaction leading to lymphedema. Clinically, podoconiosis can be distinguished from filarial elephantiasis because it is generally bilateral, it rarely involves the upper leg or groin, and it occurs at altitudes above 5,000 ft, which exceeds the level at which filariasis is transmitted. Social stigma of patients is widespread and economic development is threatened because it mainly affects the most productive people.2 Podoconiosis is preventable with low-cost measures such as shoe wearing and foot hygiene. Treatment is limited to bandaging, hosiery, elevation, and surgery in selected cases.
Figure 1.

The feet of the patient shows edema, moss-like papillomas, hard nodules and hyperkeratosis.

The feet of the patient shows edema, moss-like papillomas, hard nodules and hyperkeratosis.
  2 in total

Review 1.  Podoconiosis, a neglected tropical disease.

Authors:  D A Korevaar; B J Visser
Journal:  Neth J Med       Date:  2012-06       Impact factor: 1.422

Review 2.  Podoconiosis: non-infectious geochemical elephantiasis.

Authors:  Gail Davey; Fasil Tekola; Melanie J Newport
Journal:  Trans R Soc Trop Med Hyg       Date:  2007-10-31       Impact factor: 2.184

  2 in total
  3 in total

1.  Wuchereria bancrofti infection at four primary schools and surrounding communities with no previous blood surveys in northern Uganda: the prevalence after mass drug administrations and a report on suspected non-filarial endemic elephantiasis.

Authors:  Emmanuel Igwaro Odongo-Aginya; Alex Olia; Kilama Justin Luwa; Eiji Nagayasu; Anna Mary Auma; Geoffrey Egitat; Gerald Mwesigwa; Yoshitaka Ogino; Eisaku Kimura; Toshihiro Horii
Journal:  Trop Med Health       Date:  2017-08-15

2.  Soil iron and aluminium concentrations and feet hygiene as possible predictors of Podoconiosis occurrence in Kenya.

Authors:  Jacinta Muli; John Gachohi; Jim Kagai
Journal:  PLoS Negl Trop Dis       Date:  2017-08-23

3.  How soil scientists help combat podoconiosis, a neglected tropical disease.

Authors:  Benjamin Jelle Visser
Journal:  Int J Environ Res Public Health       Date:  2014-05-13       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.